S&P 500   3,375.06 (+0.43%)
DOW   28,112.94 (+1.16%)
QQQ   268.72 (-0.59%)
AAPL   446.45 (-0.99%)
MSFT   205.62 (-1.26%)
FB   265.33 (+0.89%)
GOOGL   1,492.58 (-0.28%)
AMZN   3,132.56 (-0.50%)
NVDA   442.28 (-0.97%)
CGC   17.46 (-2.62%)
BABA   251.15 (+1.22%)
TSLA   1,396.85 (-1.53%)
GE   6.91 (+3.60%)
MU   48.98 (-0.35%)
AMD   79.94 (-2.80%)
T   30.62 (+1.39%)
F   7.33 (+3.39%)
ACB   10.05 (-1.66%)
GILD   68.71 (+0.29%)
NFLX   476.74 (-1.37%)
DIS   131.37 (+2.00%)
BAC   27.51 (+3.58%)
BA   187.86 (+4.70%)
S&P 500   3,375.06 (+0.43%)
DOW   28,112.94 (+1.16%)
QQQ   268.72 (-0.59%)
AAPL   446.45 (-0.99%)
MSFT   205.62 (-1.26%)
FB   265.33 (+0.89%)
GOOGL   1,492.58 (-0.28%)
AMZN   3,132.56 (-0.50%)
NVDA   442.28 (-0.97%)
CGC   17.46 (-2.62%)
BABA   251.15 (+1.22%)
TSLA   1,396.85 (-1.53%)
GE   6.91 (+3.60%)
MU   48.98 (-0.35%)
AMD   79.94 (-2.80%)
T   30.62 (+1.39%)
F   7.33 (+3.39%)
ACB   10.05 (-1.66%)
GILD   68.71 (+0.29%)
NFLX   476.74 (-1.37%)
DIS   131.37 (+2.00%)
BAC   27.51 (+3.58%)
BA   187.86 (+4.70%)
S&P 500   3,375.06 (+0.43%)
DOW   28,112.94 (+1.16%)
QQQ   268.72 (-0.59%)
AAPL   446.45 (-0.99%)
MSFT   205.62 (-1.26%)
FB   265.33 (+0.89%)
GOOGL   1,492.58 (-0.28%)
AMZN   3,132.56 (-0.50%)
NVDA   442.28 (-0.97%)
CGC   17.46 (-2.62%)
BABA   251.15 (+1.22%)
TSLA   1,396.85 (-1.53%)
GE   6.91 (+3.60%)
MU   48.98 (-0.35%)
AMD   79.94 (-2.80%)
T   30.62 (+1.39%)
F   7.33 (+3.39%)
ACB   10.05 (-1.66%)
GILD   68.71 (+0.29%)
NFLX   476.74 (-1.37%)
DIS   131.37 (+2.00%)
BAC   27.51 (+3.58%)
BA   187.86 (+4.70%)
S&P 500   3,375.06 (+0.43%)
DOW   28,112.94 (+1.16%)
QQQ   268.72 (-0.59%)
AAPL   446.45 (-0.99%)
MSFT   205.62 (-1.26%)
FB   265.33 (+0.89%)
GOOGL   1,492.58 (-0.28%)
AMZN   3,132.56 (-0.50%)
NVDA   442.28 (-0.97%)
CGC   17.46 (-2.62%)
BABA   251.15 (+1.22%)
TSLA   1,396.85 (-1.53%)
GE   6.91 (+3.60%)
MU   48.98 (-0.35%)
AMD   79.94 (-2.80%)
T   30.62 (+1.39%)
F   7.33 (+3.39%)
ACB   10.05 (-1.66%)
GILD   68.71 (+0.29%)
NFLX   476.74 (-1.37%)
DIS   131.37 (+2.00%)
BAC   27.51 (+3.58%)
BA   187.86 (+4.70%)
Log in

NASDAQ:BTXBioTime Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.93
+0.02 (+2.20 %)
(As of 08/11/2020 09:30 AM ET)
Add
Compare
Today's Range
$0.88
Now: $0.93
$0.94
50-Day Range
$0.92
MA: $0.96
$0.99
52-Week Range
$0.66
Now: $0.93
$2.81
Volume807,291 shs
Average Volume719,479 shs
Market Capitalization$139.17 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. The company has collaboration with Orbit Biomedical, Ltd. BioTime, Inc. was founded in 1990 and is based in Alameda, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BTX
CUSIPN/A
CIKN/A
Phone510-521-3390

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$139.17 million
Next Earnings DateN/A
OptionableOptionable

Receive BTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BioTime (NASDAQ:BTX) Frequently Asked Questions

Has BioTime been receiving favorable news coverage?

Media stories about BTX stock have trended neutral recently, according to InfoTrie. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. BioTime earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about BioTime
.

Who are some of BioTime's key competitors?

What other stocks do shareholders of BioTime own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioTime investors own include Anavex Life Sciences (AVXL), Novavax (NVAX), SCYNEXIS (SCYX), Selecta Biosciences (SELB), Soligenix (SNGX), Sunesis Pharmaceuticals (SNSS), Trevena (TRVN), Zynerba Pharmaceuticals (ZYNE), ADMA Biologics (ADMA) and Asanko Gold (AKG).

Who are BioTime's key executives?

BioTime's management team includes the following people:
  • Dr. Stephana E. Patton, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 48)
  • Mr. Russell L. Skibsted, Chief Financial Officer (Age 60)
  • Mr. William Annett, Pres & CEO of OncoCyte Corp. (Age 65)
  • Mr. Brian M. Culley, CEO , Pres & Director (Age 48)
  • Ms. Brandi L. Roberts, CFO & Sr. VP of Fin. (Age 45)

What is BioTime's stock symbol?

BioTime trades on the NASDAQ under the ticker symbol "BTX."

What is BioTime's stock price today?

One share of BTX stock can currently be purchased for approximately $0.93.

How big of a company is BioTime?

BioTime has a market capitalization of $139.17 million.

What is BioTime's official website?

The official website for BioTime is www.biotimeinc.com.

How can I contact BioTime?

The company can be reached via phone at 510-521-3390.

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.